Scholarlink

Abstract <p>Bladder cancer (BC) is associated with different biomarkers in the human genome, many of which are located in intergenic, regulatory, and intronic regions where non-coding RNA genes and transposable elements are located. Therefore, the discovered associations affect the development of BC by changing the activity of non-coding RNA and transposable elements of the genome. This is reflected in DNA methylation changes, since microRNAs (miRNAs) serve as guides for RNA-dependent DNA methylation, and transcripts of retroelements are competing endogenous RNAs against miRNAs. Analysis of scientific literature showed the involvement of a large number of long non-coding RNAs and miRNAs in BC development. These molecules can act as both oncogenes and tumor suppressors depending on their target genes. A combined effect of long non-coding RNAs and miRNAs (TINCR/miR7, RP11-89/miR-129-5p, CASC11/miR-150, LUCAT1/miR-181c-5p, KCNQ1OT1/miR-218-5p, GAS6-AS6/miR-298, BCCE4/miR-328-3p, KCNMB2-AS1/miR-374a, SNHG1/miR-493, TUG1/miR-582-5p, UCA1/miR-582-5p, LINC00958/miR-625, DDX11-AS1/miR-2355-5p, ARAP1-AS1/miR-3918, BACH1-IT2/miR-4786) on the development of BC, as well as the role of 27 retroelement-derived miRNAs in BC carcinogenesis was demonstrated. The described activation of retroelements, which serve as drivers of epigenetic regulation was supported in a number of clinical studies. The use of the described biomarkers for diagnostics and targeted therapy of BC is suggested.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanisms of Epigenetic Factors Involvement in Bladder Cancer

  • 期刊论文

  • 发表日期：

    2025年10月7日

查看全文
  • R. N. Mustafin,
  • I. R. Gilyazova,
  • S. A. Mustafin,
  • E. K. Khusnutdinova

摘要

Abstract

Bladder cancer (BC) is associated with different biomarkers in the human genome, many of which are located in intergenic, regulatory, and intronic regions where non-coding RNA genes and transposable elements are located. Therefore, the discovered associations affect the development of BC by changing the activity of non-coding RNA and transposable elements of the genome. This is reflected in DNA methylation changes, since microRNAs (miRNAs) serve as guides for RNA-dependent DNA methylation, and transcripts of retroelements are competing endogenous RNAs against miRNAs. Analysis of scientific literature showed the involvement of a large number of long non-coding RNAs and miRNAs in BC development. These molecules can act as both oncogenes and tumor suppressors depending on their target genes. A combined effect of long non-coding RNAs and miRNAs (TINCR/miR7, RP11-89/miR-129-5p, CASC11/miR-150, LUCAT1/miR-181c-5p, KCNQ1OT1/miR-218-5p, GAS6-AS6/miR-298, BCCE4/miR-328-3p, KCNMB2-AS1/miR-374a, SNHG1/miR-493, TUG1/miR-582-5p, UCA1/miR-582-5p, LINC00958/miR-625, DDX11-AS1/miR-2355-5p, ARAP1-AS1/miR-3918, BACH1-IT2/miR-4786) on the development of BC, as well as the role of 27 retroelement-derived miRNAs in BC carcinogenesis was demonstrated. The described activation of retroelements, which serve as drivers of epigenetic regulation was supported in a number of clinical studies. The use of the described biomarkers for diagnostics and targeted therapy of BC is suggested.